Biotech
Intellia Therapeutics
Intellia Therapeutics raises $350M Follow-on Offering at $4.5B valuation
$350M
Total Raised
Follow-on Offering
Latest Round
2014
Founded
400+
Employees
40 Erie Street, Cambridge, MA 02139
1 min read
Quick Facts
Valuation
$4.5B
Latest Round Size
$350M
Latest Round Date
June 2024
Intellia Therapeutics: Follow-on Offering Funding Round
Intellia Therapeutics has successfully raised $350M in Follow-on Offering funding, reaching a valuation of $4.5B.
Company Overview
In vivo CRISPR gene editing
Funding Details
The Follow-on Offering round was led by Atlas Venture, with participation from Novartis Venture Fund, Venrock, Lilly Asia Ventures.
Company Information
- Headquarters: 40 Erie Street, Cambridge, MA 02139
- Founded: 2014
- Employees: 400+
- Category: Biotech
Investment
Intellia Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Atlas Venture: Verified investor in Follow-on Offering
- Novartis Venture Fund: Verified investor in Follow-on Offering
- Venrock: Verified investor in Follow-on Offering
- Lilly Asia Ventures: Verified investor in Follow-on Offering
Key Investors
Atlas Venture
Lead Investor
Verified investor in Follow-on Offering
Novartis Venture Fund
Investor
Verified investor in Follow-on Offering
Venrock
Investor
Verified investor in Follow-on Offering
Lilly Asia Ventures
Investor
Verified investor in Follow-on Offering
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M